Yıl: 2010 Cilt: 44 Sayı: 2 Sayfa Aralığı: 323 - 338 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol

Öz:
Son üç dekadda bağışıklığı baskılanmış hasta sayısının artması ve bu hastaların yaşam sürelerinin uzamasına paralel olarak Aspergillus enfeksiyonlarının insidansı da giderek artmıştır. Ayrıca son zamanlarda klasik bağışıklık yetmezliği olan hastaların dışında yoğun bakım ünitesinde yatan veya kronik obstrüktif akciğer hastalığı olan hastalar gibi bazı hasta gruplarında da aspergilloz insidansının arttığı bildirilmiştir. Bu enfeksiyonlar hastane dışında da kazanılabilmekle birlikte, önemli bir kısmı hastanın hastanede yattığı süre içinde ortaya çıkmaktadır. Aspergillus sporları sıklıkla solunum yollarından bulaşır, ancak nadiren sindirim yolu veya bütünlüğü bozulmuş deriden girerek de enfeksiyona yol açabilirler. Hastane kaynaklı aspergillozda en sık saptanan etkenler Aspergillus fumigatus ve Aspergillus flavus’tur. Enfeksiyonların özgün klinik bulgularının olmaması ve tanı ve tedavideki zorluklar nedeniyle hastane kaynaklı aspergillozdan korunma büyük önem taşımaktadır. Bu derleme yazıda, hastane kaynaklı aspergillozun epidemiyolojisi ve kontrolü irdelenmektedir.
Anahtar Kelime:

Konular: Mikrobiyoloji Temel Sağlık Hizmetleri Sağlık Bilimleri ve Hizmetleri Pediatri

Nosocomial aspergillosis: Epidemiology and control

Öz:
In the last three decades, in accordance with the increase in the number of immunocompromised patients and their prolonged life-span, the incidence of Aspergillus infections has increased. Furthermore, in addition to immunocompromised patients, an increase in the incidence of aspergillosis was also detected in patients hospitalised in intensive care units and in patients with chronic obstructive pulmonary disease. Although aspergillosis can be acquired in the community, a considerable number of the cases is healthcare-associated. The primary route of Aspergillus acquisition is via inhalation, however, entry through gastrointestinal tract or damaged skin may also be possible. Aspergillus fumigatus and Aspergillus flavus are the most common species isolated from healthcare-associated infections. The clinical spectrum of the infection includes respiratory, cutaneous, sinusal and rhino-cerebral manifestations. Since clinical signs are not specific and diagnosis and treatment present difficulties, prevention of health-care associated aspergillosis is of special importance. In this review article, the epidemiology and control of nosocomial aspergillosis have been discussed.
Anahtar Kelime:

Konular: Mikrobiyoloji Temel Sağlık Hizmetleri Sağlık Bilimleri ve Hizmetleri Pediatri
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik
  • 1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
  • 2. Richardson MD. Changing pattern and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56(Suppl 1): 5-11.
  • 3. Beck-Sague CM, Jarvis WR, and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-51.
  • 4. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
  • 5. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital epidemiology. J Infect 1996; 33: 23-32.
  • 6. Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis and treatment. Infect Dis Clin North Am 2006; 20: 545-61.
  • 7. VandenBergh MF, Verweij PE, Voss A. Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. Diagn Microbiol Infect Dis 1999; 34: 221-7.
  • 8. Warris A, Voss A, Verweij PE. Hospital sources of Aspergillus species: new routes of transmission. Rev Iberoam Micol 2001; 18: 156-62.
  • 9. Bouakline A, Lacroix C, Roux N, Gangneux JP, Derouin F. Fungal contamination of food in hematology units. J Clin Microbiol 2000; 38: 4272-3.
  • 10. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002; 34: 780-9.
  • 11. Arnow PM, Sadigh M, Costas C, Weil D, Chudy R. Endemic and epidemic aspergillosis associated with inhospital replication of Aspergillus organisms. J Infect Dis 1991; 1: 998-1002.
  • 12. Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentration of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998; 36:165-8.
  • 13. Patterson JE, Zidouh A, Miniter P, Andriole WT, Patterson TF. Hospital epidemiologic surveillance for invasive aspergillosis: patients demographics and the utility of antigen detection. Infect Control Hosp Epidemiol 1997; 18: 104-8.
  • 14. Fourneret-Vivier A, Lebeau B, Mallaret MR, et al. Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002). J Hosp Infect 2006; 62: 22-8.
  • 15. Debeaupuis JP, Sarfati J, Chazalet F, Latge JF. Genetic diversity among clinical and environmental isolates of Aspergillus fumigatus. Infect Immun 1997; 65: 3080-5.
  • 16. Einsele H, Quabeck K, Muller KD, et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998; 352: 1443.
  • 17. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006; 63: 246-54.
  • 18. Pasqualotto AC, Denining D. Postoperative aspergillosis. Clin Microbiol Infect Dis 2006; 12: 1060-76.
  • 19. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
  • 20. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Wijngaerden EV. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-5.
  • 21. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker J, and the Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hopitaux de Paris. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris Area. J Hosp Infect Dis 2002; 51: 288-96.
  • 22. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11: 427-9.
  • 23. Garnacho-Montero J, Amaya-Willar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191-9.
  • 24. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10: R31.
  • 25. Marr KA, Carter RA, Boeckh M, Martin P, Core L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
  • 26. Grow WB, Moreb SJ, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Morrow Transplant 2002; 29: 15-9.
  • 27. Saracli MA, Mutlu FM, Yildiran ST, et al. Clustering of invasive Aspergillus ustus eye infections in a tertiary care hospital: a molecular epidemiologic study of an uncommon species. Med Mycol 2007; 45: 377-84.
  • 28. Gunaratne PS, Wijeyaratne CN, et al. An outbreak of Aspergillus meningitis following spinal anaesthesia for caesarean section in Sri Lanka: a post-tsunami effect? Ceylon Med J 2006; 51: 137-42.
  • 29. Panackal AA, Dahlman A, Keil KT, et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 2003; 75: 1050-3.
  • 30. Vandecasteele SJ, Boelaert JR, Verrelst P, Graulus E, Gordts BZ. Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery. Clin Infect Dis 2002; 35: 887-90.
  • 31. Myoken Y, Sugata T, Fujita Y, et al. Molecular epidemiology of invasive stomatitis due to Aspergillus flavus in patients with acute leukemia. J Oral Pathol Med 2003; 32: 215-18.
  • 32. Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet contamination. Infect Control Hosp Epidemiol 1994; 15: 221-2.
  • 33. Grossman ME, Fithian EC, Behrens C, Bissinger J, Fracaro M, Neu HC. Primary cutaneous aspergillosis in six leukemic children. Am Acad Dermatol 1985; 12: 313-18.
  • 34. Sarubbi FA, Kopf HB, Wilson MB, McGinnis MR, Rutala WA. Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis 1982; 125:33-8.
  • 35. Haiduven D. Nosocomial aspergillosis and building construction. Medical Mycology 2009; 47(Suppl 1): S210-6.
  • 36. Morgan J, Wannemuehler KA, Mar KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (Suppl 1): S49-58.
  • 37. Lin SJ, Shranz J, Teusch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
  • 38. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis related hospitalisation in the United States. Clin Infect Dis 2000; 31: 1524-8.
  • 39. Centers for Disease Control and Prevention. Guidelines for environmental infection control in healthcare facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HIC-PAC). MMWR 2003; 52 (No.RR-10): 1-44.
  • 40. Siegel JD, Rhinehart E, Jackson M, Chiarello L and the Healthcare Infection Practices Advisory Committee. 2007 Guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ guidelines/Isolation 2007.pdf
  • 41. American Institute of Architects (AIA). Guidelines for Design and Construction of Health Care Facilities. 2006, The Facilities Guideline Institute, Washington, DC.
  • 42. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53(RR-3): 1-36.
  • 43. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19: 571-76.
  • 44. Maertens J, Frere P, Lass-Flörl C, Heinz W, Cornely O. European guidelines for primary antifungal prophylaxis in leukemia patients. Presented at the 14th International Symposium of Infections in the Immunocompromised Host. July 2-5, 2006. Crans-Montana, Switzerland.
  • 45. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
  • 46. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versushost disease. N Engl J Med 2007; 356: 335-47.
  • 47. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Hematol 2007; 78: 275-82.
  • 48. Sispas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42: 1584-91.
APA EROL S (2010). Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. , 323 - 338.
Chicago EROL Serpil Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. (2010): 323 - 338.
MLA EROL Serpil Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. , 2010, ss.323 - 338.
AMA EROL S Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. . 2010; 323 - 338.
Vancouver EROL S Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. . 2010; 323 - 338.
IEEE EROL S "Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol." , ss.323 - 338, 2010.
ISNAD EROL, Serpil. "Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol". (2010), 323-338.
APA EROL S (2010). Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. Mikrobiyoloji Bülteni, 44(2), 323 - 338.
Chicago EROL Serpil Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. Mikrobiyoloji Bülteni 44, no.2 (2010): 323 - 338.
MLA EROL Serpil Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. Mikrobiyoloji Bülteni, vol.44, no.2, 2010, ss.323 - 338.
AMA EROL S Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. Mikrobiyoloji Bülteni. 2010; 44(2): 323 - 338.
Vancouver EROL S Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol. Mikrobiyoloji Bülteni. 2010; 44(2): 323 - 338.
IEEE EROL S "Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol." Mikrobiyoloji Bülteni, 44, ss.323 - 338, 2010.
ISNAD EROL, Serpil. "Hastane kaynaklı aspergilloz: Epidemiyoloji ve kontrol". Mikrobiyoloji Bülteni 44/2 (2010), 323-338.